{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in a-synuclein (A30P and A53T) cause familial autosomal dominant PD... Expression of human wild-type or mutant a-synuclein in transgenic mice and Drosophila mimics several aspects of PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism for Parkinson's disease (PD) as involving abnormal accumulation of a-synuclein in Lewy bodies and neuronal degeneration, with mutations like A30P contributing to familial PD through similar phenotypic effects as sporadic PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We used stable human neuronal cell lines (BE2-M17) over-expressing wild-type or mutant human a-synuclein... to monitor global alterations in gene expression levels using the Affymetrix U95A oligonucleotide array.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (gene expression profiling via microarrays in a neuronal cell line model) is applicable as it models the transcriptional effects of a-synuclein mutations, which are relevant to PD pathogenesis involving protein accumulation and neuronal dysfunction.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Total RNA prepared from four cell lines (two each over-expressing wild-type and A53T a-synuclein), and one cell line containing pcDNA3 vector alone were hybridized... Pairwise comparisons with the vector-only cell line were carried out... Reactions were performed in a 20-lL volume... confirmed on at least two separate reaction plates.",
          "judgment": "Yes",
          "reasoning": "Basic controls are present (vector-only cell line as a negative control). Replicates are mentioned (multiple clonal lines and repeated measurements), satisfying the criteria for experimental repetition.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "No explicit mention of known pathogenic or benign variant controls beyond comparing wild-type and mutant (A30P, A53T) a-synuclein.",
          "judgment": "No",
          "reasoning": "The paper does not mention the use of known pathogenic or benign variant controls beyond the mutants under study (A30P and A53T). There is no evidence of variants reaching P/LP or B/LB criteria without relying on PS3/BS3.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA A30P is rated as PS3_supporting due to the use of relevant gene expression assays in a neuronal cell model that reflect PD pathogenesis. However, the lack of specific variant controls limits the strength to supporting level."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in a-synuclein (A30P and A53T) cause familial autosomal dominant PD... Expression of human wild-type or mutant a-synuclein in transgenic mice and Drosophila mimics several aspects of PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism for PD as involving abnormal accumulation of a-synuclein in Lewy bodies and neuronal degeneration, with mutations like A53T contributing to familial PD through similar phenotypic effects as sporadic PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We used stable human neuronal cell lines (BE2-M17) over-expressing wild-type or mutant human a-synuclein... to monitor global alterations in gene expression levels using the Affymetrix U95A oligonucleotide array.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (gene expression profiling via microarrays in a neuronal cell line model) is applicable as it models the transcriptional effects of a-synuclein mutations, which are relevant to PD pathogenesis involving protein accumulation and neuronal dysfunction.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Total RNA prepared from four cell lines (two each over-expressing wild-type and A53T a-synuclein), and one cell line containing pcDNA3 vector alone were hybridized... Pairwise comparisons with the vector-only cell line were carried out... Reactions were performed in a 20-lL volume... confirmed on at least two separate reaction plates.",
          "judgment": "Yes",
          "reasoning": "Basic controls are present (vector-only cell line as a negative control). Replicates are mentioned (multiple clonal lines and repeated measurements), satisfying the criteria for experimental repetition.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "No explicit mention of known pathogenic or benign variant controls beyond comparing wild-type and mutant (A30P, A53T) a-synuclein.",
          "judgment": "No",
          "reasoning": "The paper does not mention the use of known pathogenic or benign variant controls beyond the mutants under study (A30P and A53T). There is no evidence of variants reaching P/LP or B/LB criteria without relying on PS3/BS3.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA A53T is rated as PS3_supporting due to the use of relevant gene expression assays in a neuronal cell model that reflect PD pathogenesis. However, the lack of specific variant controls limits the strength to supporting level."
    }
  ]
}